Keros Therapeutics director Jean Jacques Bieneaime acquires USD 10,270 in common shares
KROS•Director buys 1,000 shares
Keros Therapeutics director Jean Jacques Bienaime bought 1,000 common shares at a weighted average of USD 10.27.
- Directly held stake rose to 19,592 shares.
